Trial of Methylene Dimethane Sulphonate in Ovarian Cancer
Author Information
Author(s): D.B. Smith, M.J. Lind, S.B. Kaye, E.S. Newlands, G.R.P. Blackledge, A. Gibson
Primary Institution: CRC Department of Medical Oncology, Charing Cross Hospital
Hypothesis
Is methylene dimethane sulphonate (MDMS) effective in treating advanced ovarian cancer?
Conclusion
MDMS is not effective for patients with advanced ovarian cancer who have received prior chemotherapy.
Supporting Evidence
- All patients had received prior chemotherapy.
- MDMS was administered as an intravenous bolus injection.
- Major toxicity observed was thrombocytopenia.
- No objective remissions were seen during the study.
- Three patients had stable disease lasting at least 8 weeks.
Takeaway
Doctors tried a new medicine called MDMS on women with advanced ovarian cancer, but it didn't help them get better.
Methodology
MDMS was given to 19 patients with advanced ovarian cancer, and their responses were evaluated after treatment.
Limitations
The study had a small sample size and no objective remissions were observed.
Participant Demographics
Patients had advanced epithelial ovarian cancer, median age 54, with various stages and histologies.
Want to read the original?
Access the complete publication on the publisher's website